Table 1.

Reported odds ratios and 95% confidence intervals of neurological adverse events with the Influenza, AstraZeneca, Moderna, and Pfizer-BioNTech vaccines

Adverse event	Influenza	AstraZeneca	Moderna	Pfizer-BioNTech
Cerebral venous sinus thrombosis	^a1/263,796 ^b(0.06, 0.01–0.46)	351/393,877 (15.43, 13.73–17.34)	23/149,016 (2.67, 1.77–4.03)	91/357,991 (4.40, 3.56–5.44)
Guillain–Barre syndrome	3618/263,796 (53.96, 51.80–56.21)	428/393,877 (2.74, 2.49–3.02)	103/149,016 (1.74, 1.43–2.12)	217/357,991 (1.53, 1.34–1.75)
Hemorrhagic stroke	10/263,796 (0.14, 0.07–0.25)	58/393,877 (0.53, 0.41–0.69)	30/149,016 (0.72, 0.50–1.04)	82/357,991 (0.82, 0.66–1.02)
Ischemic stroke	27/263,796 (0.24, 0.16–0.35)	358/393,877 (2.13, 1.92–2.37)	99/149,016 (1.56, 1.28–1.90)	417/357,991 (2.73, 2.48–3.01)
Transient ischemic attack	80/263,796 (0.30, 0.24–0.37)	552/393,877 (1.38, 1.27–1.50)	150/149,016 (0.99, 0.84–1.16)	452/357,991 (1.24, 1.13–1.36)

Adverse event

Influenza

AstraZeneca

Moderna

Pfizer-BioNTech

Cerebral venous sinus thrombosis

^a1/263,796

^b(0.06, 0.01–0.46)

351/393,877

(15.43, 13.73–17.34)

23/149,016

(2.67, 1.77–4.03)

91/357,991

(4.40, 3.56–5.44)

Guillain–Barre syndrome

3618/263,796

(53.96, 51.80–56.21)

428/393,877

(2.74, 2.49–3.02)

103/149,016

(1.74, 1.43–2.12)

217/357,991

(1.53, 1.34–1.75)

Hemorrhagic stroke

10/263,796

(0.14, 0.07–0.25)

58/393,877

(0.53, 0.41–0.69)

30/149,016

(0.72, 0.50–1.04)

82/357,991

(0.82, 0.66–1.02)

Ischemic stroke

27/263,796

(0.24, 0.16–0.35)

358/393,877

(2.13, 1.92–2.37)

99/149,016

(1.56, 1.28–1.90)

417/357,991

(2.73, 2.48–3.01)

Transient ischemic attack

80/263,796

(0.30, 0.24–0.37)

552/393,877

(1.38, 1.27–1.50)

150/149,016

(0.99, 0.84–1.16)

452/357,991

(1.24, 1.13–1.36)

Bold values indicate significant signals

^aReported number of the ocular events for that vaccine/number of total reported events for that vaccine

^bOdds ratio, 95% confidence interval